Foundational guide
FOXO4-DRI Dosage: The Inputs a Dose Would Require
A dose is the output of a measurement chain. This compound is missing every link in that chain for humans, and the vial it would be drawn from does not reliably contain its labelled mass either.
FOXO4-DRI dosage has no established human answer, and the reason is worth stating precisely rather than as a disclaimer. A dose is not a number someone has used; it is the output of a measurement chain, and for this compound every link in that chain is absent in humans.
This guide sets out what the animal work used, which inputs a human dose would require, and a separate problem that affects even laboratory work: the vial does not reliably contain what its label says.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
What the published animal work administered
The foundational study reports its dosing explicitly, which makes it possible to describe rather than infer.
Mice received FOXO4-DRI at 5 mg/kg, three times, on alternating days: day 1, day 3 and day 5. Administration was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. Doxorubicin, used to induce senescence in that model, was administered separately at 10 mg/kg in mice.
Two features are consistently misdescribed in secondary sources. The schedule was intermittent rather than continuous, three administrations across five days. And both routes are laboratory routes; intraperitoneal injection has no routine human application outside specific clinical circumstances.
Subsequent studies set their own parameters for their own models: aged mouse Leydig cells, keloid fibroblasts, murine pulmonary fibrosis, human chondrocytes in culture. None was a dose-finding exercise for people.
The pharmacokinetic inputs a human dose would need
Allometric scaling is frequently invoked to bridge from rodent doses to human ones. It is a legitimate method for estimating a starting point for formal study, and it requires inputs that do not exist here.
Scaling presumes knowledge of how a compound is absorbed, distributed, metabolised and cleared in the target species. For FOXO4-DRI in humans, none of these has been measured.
The D-retro-inverso construction complicates the estimate further. The molecule is specifically engineered to resist protease degradation, which should extend its persistence relative to a conventional peptide. By how much, in a human body, has never been determined, so even the direction of the correction is better characterised than its magnitude.
| Input | Status in humans | Consequence if absent |
|---|---|---|
| Half-life | Never measured | Dosing interval undeterminable |
| Bioavailability | Never measured | Route comparison impossible |
| Clearance route | Never measured | Organ-impairment adjustment impossible |
| Volume of distribution | Never measured | Loading calculation impossible |
| Maximum tolerated dose | Never established | No upper bound |
| Target exposure | Never defined | No endpoint to aim at |
The arithmetic problem that precedes dosing
Before any dose question arises, there is a concentration question, and this is where a checkable error is being made routinely.
Concentration is mass divided by volume. The mass most people use is the number printed on the vial, and for this product the label and the assays disagree. Kovera Labs measured 11.41 mg on batch 55-05260628; MZ Biolabs measured 8.30 mg on lot 55-01260229. Both vials read 10 mg.
Anyone reconstituting the January lot on the label assumption produces a solution roughly 17% weaker than recorded, and every volume drawn inherits that error. No downstream precision corrects an incorrect starting mass.
| Starting mass | 1 mL | 2 mL | 3 mL |
|---|---|---|---|
| 10 mg, label | 10.00 mg/mL | 5.00 mg/mL | 3.33 mg/mL |
| 11.41 mg, Kovera | 11.41 mg/mL | 5.71 mg/mL | 3.80 mg/mL |
| 8.30 mg, MZ Biolabs | 8.30 mg/mL | 4.15 mg/mL | 2.77 mg/mL |
Why intermittent, and what that implies
The alternating-day schedule reflects a mechanistic rationale rather than a tolerability constraint, and understanding it explains why continuous-exposure vocabulary does not transfer.
A senolytic eliminates a cell population. Once that population is cleared there is nothing further for the compound to act on until senescent cells re-accumulate, which occurs over months to years. Continued exposure adds whatever risk the compound carries without a corresponding benefit, and selectivity is relative rather than absolute, so prolonged exposure widens the opportunity for off-target effects.
The mechanism itself was characterised structurally in 2025: the disordered transactivation domain of p53 is the binding target of both FOXO4 and FOXO4-DRI. Mechanistic clarity of that kind is sometimes mistaken for clinical readiness. It is not the same thing, and no trial has followed.
Frequently asked questions
- What is the correct FOXO4-DRI dosage?
- There is no established human dosage. No phase 1 trial has been conducted, so no dose has been validated and no tolerability ceiling determined.
- What dose did the animal studies use?
- 5 mg/kg, three administrations on alternating days, days 1, 3 and 5. Route was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts.
- Can allometric scaling produce a human dose?
- Not a validated one. Scaling requires pharmacokinetic inputs including half-life, bioavailability, clearance and volume of distribution. None has been measured for this peptide in humans.
- Why does the vial fill matter for dosing?
- Because concentration derives from starting mass. The two published batches assayed 11.41 mg and 8.30 mg against a 10 mg label, so reconstituting on the label can put a solution 17% out before anything else happens.
Limitations of the evidence
This guide does not provide a human dose and cannot. No phase 1 trial has established tolerability or pharmacokinetics for FOXO4-DRI in humans, so any figure derived by scaling from rodent data would be an extrapolation without validation. The animal doses reported here are described as experimental parameters, not as a basis for calculation.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Bourgeois B, Spreitzer E, Platero-Rochart D, et al. · The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI · Nature Communications · 2025PMID 40593617Preclinical
- 3.Circulation · Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation · 2023PMID 36515093Preclinical